Ozempic, an FDA-approved therapy for sort 2 diabetes, blew up when folks started utilizing it as a weight reduction drug. Since then, varied medical research have discovered that the important thing ingredient, semaglutide, has helped folks affected by kidney well being, coronary heart well being, drug dependancy and Alzheimer’s illness.
However new analysis is exhibiting some unfavourable uncomfortable side effects of the drug, together with muscle loss.
A world crew revealed a research in The Lancet medical journal this month with preliminary outcomes that present barely greater charges of non-fat tissue loss in comparison with weight reduction from means apart from prescribed drugs.
Though there’s some concern, the researchers don’t recommend those that take Ozempic utterly cease it.
“These highly effective medications should be used strategically,” the research mentioned. “This strategy can be accomplished with concurrent nutrition and exercise interventions.”
Dr. Dave Montgomery, NewsNation’s medical contributor and a board-certified heart specialist, mentioned he is not sounding the alarm.
“This report is nearly one thing that we see throughout the board with weight reduction,” Montgomery said Friday on NewsNation’s “Morning in America.”
“When there are large amounts of weight loss over a short period of time, we not only see fat loss, we also see muscle loss, so that’s a physiologic principle,” he added.
Montgomery additionally famous that research like this can refine the affected person pool. People who find themselves depending on bone muscle mass, reminiscent of post-menopausal girls, could not profit as a lot.
“If this turns out, when they research it, to be a problem with losing too much muscle, which makes strong bone, then we’ll have to say maybe we shouldn’t give it to every post-menopausal woman,” he mentioned as one instance.
Muscle loss could be improved with power and endurance coaching and elevated protein in a single’s food plan.
NewsNation is owned by Nexstar Media Group, which additionally owns The Hill.
